French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients.

Context: In France, gemcitabine plus nab-paclitaxel (GEM-NAB) is heterogeneously used in metastatic pancreatic cancer due to disparities in its financial accessibility in the institutions.

Objectives: GEM-NAB conduct a French multi-institutional cost-effectiveness analysis of GEM-NAB gemcitabine alone (GEM) as second-line treatment in pancreatic cancer patients.

Design: All the unresected metastatic pancreatic ductal adenocarcinoma (PDAC) consecutive patients who received GEM-NAB (institution 1) or GEM alone (institutions 2 and 3) as second-line treatment after failure of a 5-fluorouracil based systemic chemotherapy regimen were screened.